Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers.
ACS medicinal chemistry letters May 8, 2025 DOI: 10.1021/acsmedchemlett.5c00180 via PubMed
Summary
AI-generated from the abstractDMT produces fast-acting antidepressant effects, but its use is limited by acute side effects like high blood pressure and rapid heart rate. This work describes coformulations of DMT with short-acting beta-blockers or nitrates that are matched to DMT's pharmacokinetics. These combinations reduce peripheral cardiovascular risks without interfering with the central therapeutic effects, potentially enabling safer psychedelic therapy for vulnerable populations.
Study at a glance
| Characteristics | Descriptive study Peer reviewed |
|---|---|
| Interventions | beta-blockers nitrates |
| Topics | Psychedelic-assisted therapy |
| Keywords | Cardiovascular medicine Mental health treatment Drug safety Medical research |
| Citations | 1 |
| Key finding | Coformulating DMT with short-acting beta-blockers or nitrates matched to its pharmacokinetics can mitigate cardiovascular risks while preserving central therapeutic action. |
Abstract
DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in vulnerable populations.